Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients

• Published in: Neoplasia (New York, N.Y.) Vol. 19; no. 4; pp. 255 - 260
• Main Authors: Frankel, Arthur E, Eskiocak, Ugur, Gill, Jennifer G, Yuan, Stacy, Ramesh, Vijayashree, Froehlich, Thomas W, Ahn, Chul, Morrison, Sean J
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-04-2017; Neoplasia Press; Elsevier
• Subjects: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Digoxin - administration & dosage; Disease Models, Animal; Female; Humans; Male; Melanoma - drug therapy; Melanoma - genetics; Melanoma - pathology; Mice; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oncology; Original article; Proto-Oncogene Proteins B-raf - genetics; Pyridones - administration & dosage; Pyrimidinones - administration & dosage; Retreatment; Treatment Outcome; Xenograft Model Antitumor Assays
• ISSN: 1476-5586; 1522-8002; 1476-5586
• DOI: 10.1016/j.neo.2017.01.010

Abstract This is the first prospective study of a combination therapy involving a cardenolide and a MEK inhibitor for metastatic melanoma. Whereas BRAF mutant melanomas can exhibit profound responses to treatment with BRAF and MEK inhibitors, there are fewer options for BRAF wild-type melanomas. In preclinical studies, we discovered that cardenolides synergize with MEK inhibitor to promote the regression of patient-derived xenografts irrespective of BRAF mutation status. We therefore conducted a phase 1B study of digoxin 0.25 mg and trametinib 2 mg given orally once daily in 20 patients with advanced, refractory, BRAF wild-type melanomas. The most common adverse events were rash, diarrhea, nausea, and fatigue. The response rate was 4/20 or 20% with response durations of 2, 4, 6, and 8 months. The disease control rate (including partial responses and stable disease) was 13/20 or 65% of patients, including 5/6 or 83% of patients with NRAS mutant melanomas and 8/14 or 57% of NRAS wild-type melanomas. Patients with stable disease had disease control for 2, 2, 2, 4, 5, 6, 7, 10, and 10 months. Xenografts from four patients recapitulated the treatment responses observed in patients. Based on these pilot results, an expansion arm of digoxin plus MEK inhibitor is warranted for NRAS mutant metastatic melanoma patients who are refractory or intolerant of immunotherapy. Key points Digoxin plus trametinib is well tolerated and achieves a high rate of disease control in BRAF wild-type metastatic melanoma patients.